ISRG: Inverse Head And Shoulders detected on 30 Sep 2026

ISRG is forming an inverse head-and-shoulders pattern after shares came under pressure with the broader medtech industry. The stock currently trades at $412.18, well above the key support level at $345.25 but beneath resistance at $370.57. With a structure score of 10.0 and volume score of 10.0, the pattern exhibits textbook symmetry and heavy volume confirmation on the recent rebound. The breakout score of 8.0 suggests moderate strength. At current levels, ISRG sits 31.74% below its 52-week high and 25.45% above its 52-week low, positioned favorably within its recovery range. RSI at 67.21 indicates advancing momentum but shows early overbought conditions approaching 70.

On September 28, 2026, Intuitive Surgical received CE mark approval for using its da Vinci SP system in transvaginal gynecologic procedures, a first-of-its-kind indication that expands the robot's minimally invasive surgery footprint in Europe. The main reason behind Intuitive Surgical's slide this year is slowing procedure growth for its da Vinci surgical robots; in Q4 2025 da Vinci procedure volumes rose 17%, while in the latest quarter growth was 15%. Trade-ins reached 144 in fiscal Q2 2026, up from 83 a year earlier, mostly from customers moving to the new da Vinci 5 robot, and the average purchased da Vinci system sold for $1.6 million, up from $1.5 million a year earlier. Ion's 36% procedure growth in Q2 2026 to 48,000 quarterly procedures shows a second platform gaining traction. This recent regulatory win and trade-in momentum provide technical support for the inverse H&S pattern forming after a prolonged decline.

A successful breakout above the $370.57 resistance would target the conservative measured move of $431.70, representing approximately 5% upside from current levels. This aligns with the 58.46% win probability score. Volume confirmation will be critical—the pattern needs breakout volume above the 20-day average of 2.45M shares to validate continuation. Current volume is running at 77% of average, suggesting accumulation is moderate. The invalidation level sits at $345.25 key support; a breakdown below this level negates the inverse H&S setup and signals the decline may resume. Breakout timing suggests completion in the coming 2-4 weeks as the pattern nears maturity.

Procedure volume growth is the primary concern, with the company projecting full-year da Vinci procedure growth of 13.5% to 15.5%—representing meaningful deceleration from prior years. US growth moderated in fiscal Q2 2026, mostly in procedures patients can put off, with some customers linking that to changes in patient coverage and premiums. The increased use of GLP-1 weight-loss drugs is one factor in this slowdown; CFO acknowledged that U.S. da Vinci bariatric cases declined by a high single-digit percentage in Q2. RSI at 67.21 shows elevated momentum risk. Beta of 0.16 provides downside stability, but elevated volatility (20-day at 28.23%) and elevated 2-week gain (9.29%) suggest potential pullback risk. Volume ratio at 0.77 indicates below-average participation, which could limit breakout conviction if volume doesn't increase meaningfully.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.